Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zealand Pharma A/S (ZEAL) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Anna Krassowska - VP of IR and Corporate Communications Adam Steensberg - President and CEO Matt Dallas - SVP and CFO David Kendall - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham and Company Lucy Codrington - Jefferies Michael Novod - Nordea Thomas Bowers - Danske Bank Operator Good day, and thank you for standing by. Welcome to the Zealand Pharma Second Quarter 2022 Financial Results Conference Call and Webcast.

Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript

Zealand Pharma Announces Financial Results for the First Half of 2022

NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”)REPRESENTING DEPOSITED ORDINARY SHARES OF:ZEALAND PHARMA A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 98920Y304 AND UNDERLYING ISIN: DK0060257814

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market

Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022

Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?

PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Iktos' AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug dis

Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design

Company announcement – No. 29 / 20 2 2

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

Company announcement – No. 28  / 202 2

Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022

C OMPANY A NNOUNCEMENT – NO. 27 / 202 2

Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity

Zealand Pharma to Participate in Upcoming Investor Conferences

Zealand Pharma Announces Appointment of David M. Kendall, M.D.

Zealand Pharma announces directed issue and private placement corresponding to approx. 6.6 % of existing share capital

Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide

Company announcement – No. 23 / 20 2 2

Zealand Pharma launches long-term incentive program for Zealand's Corporate Management and employees for 2022

Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance. Based on the trial's.

Why Zealand Pharma Shares Are Rising

Zealand Pharma A/S (NASDAQ: ZEAL) has announced topline results from its second Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI), a condition in which individuals have abnormally high levels of insulin. Dasiglucagon met the trial's.

Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher

U.S.-listed shares of Zealand Pharma ZEAL, +1.83% ZEAL, +18.99% soared 21.2% in premarket trading on Thursday after the company said a Phase 3 clinical trial evaluating its investigational treatment for babies with a rare genetic disorder met the primary endpoint. Zealand is testing dasiglucagon as a treatment for pediatric patients with congenital hyperinsulinism, which causes excess insulin secretion and low blood sugar.

Zealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babies

Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)

Zealand Pharma Announces Asset Purchase Agreement with MannKind Corporation for V-Go® Insulin Delivery Device

Zealand Pharma A/S (ZEAL) Q1 2022 Earnings Conference Call May 12, 2022 10:00 AM ET Company Participants Matt Dallas - SVP and CFO Adam Steensberg - President and CEO Conference Call Participants Thomas Bowers - Danske Bank Joseph Stringer - Needham Lucy Codrington - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Zealand Pharma Results for Q1 2022 Conference Call. At this time, all participants are in a listen-only mode.

Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q1 2022 Earnings Call Transcript

Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities [CORRECTED]

Zealand Pharma Provides Update on Refocused Strategy Prioritizing Research and Development

C ompany a nnouncement – No. 16 / 202 2

Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company's Refocused Strategy

Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022

News for Zealand Pharma Stock (ZEAL)